1. Home
  2. MDWD vs RELL Comparison

MDWD vs RELL Comparison

Compare MDWD & RELL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • RELL
  • Stock Information
  • Founded
  • MDWD 2000
  • RELL 1947
  • Country
  • MDWD Israel
  • RELL United States
  • Employees
  • MDWD N/A
  • RELL N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • RELL Electronic Components
  • Sector
  • MDWD Health Care
  • RELL Technology
  • Exchange
  • MDWD Nasdaq
  • RELL Nasdaq
  • Market Cap
  • MDWD 184.8M
  • RELL 198.6M
  • IPO Year
  • MDWD 2014
  • RELL N/A
  • Fundamental
  • Price
  • MDWD $17.75
  • RELL $14.87
  • Analyst Decision
  • MDWD Strong Buy
  • RELL
  • Analyst Count
  • MDWD 1
  • RELL 0
  • Target Price
  • MDWD $25.00
  • RELL N/A
  • AVG Volume (30 Days)
  • MDWD 56.9K
  • RELL 61.0K
  • Earning Date
  • MDWD 11-26-2024
  • RELL 01-13-2025
  • Dividend Yield
  • MDWD N/A
  • RELL 1.59%
  • EPS Growth
  • MDWD N/A
  • RELL N/A
  • EPS
  • MDWD N/A
  • RELL N/A
  • Revenue
  • MDWD $19,720,000.00
  • RELL $197,604,000.00
  • Revenue This Year
  • MDWD $10.37
  • RELL $15.93
  • Revenue Next Year
  • MDWD $26.36
  • RELL $11.34
  • P/E Ratio
  • MDWD N/A
  • RELL N/A
  • Revenue Growth
  • MDWD N/A
  • RELL N/A
  • 52 Week Low
  • MDWD $11.04
  • RELL $8.08
  • 52 Week High
  • MDWD $24.00
  • RELL $15.51
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 53.40
  • RELL 61.23
  • Support Level
  • MDWD $17.33
  • RELL $13.65
  • Resistance Level
  • MDWD $18.25
  • RELL $14.41
  • Average True Range (ATR)
  • MDWD 0.75
  • RELL 0.61
  • MACD
  • MDWD 0.05
  • RELL 0.05
  • Stochastic Oscillator
  • MDWD 73.68
  • RELL 71.68

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About RELL Richardson Electronics Ltd.

Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. Its products have applications in alternative energy, healthcare, aviation, broadcast, communications, industrial, marine, medical, military, scientific, and semiconductor markets. The company segments include PMT (Power and Microwave Technologies Group), Canvys, (Green Energy Solutions) GES, and Healthcare reportable segments. The company derives the majority of its revenues from the PMT segment.

Share on Social Networks: